Latest Content

Experts at the 2026 APAO Symposium highlighted patient education, clinical trial updates, and professional development in cancer care.

Kennon McCollum explains how psychosocial, physical, and financial barriers impact treatment selection for patients with CLL.

Learn how oncology nurses can leverage clinical strategies, baseline testing, and targeted referrals to optimize patient vitamin D during treatment.

Adding anti-obesity medication for survivors who do not respond early to lifestyle changes helps 42% achieve clinically meaningful weight loss.

Andrew Evens, DO, and Joanna Rhodes, MD, discuss evolving CLL treatment paradigms, CAR T-cell therapy versus bispecific antibodies, and expanding community access to specialized lymphoma care.

A JAMA study of 73,042 veterans shows active surveillance for low-risk prostate cancer rose to 93%, with notable racial and social disparities.

How oncology nurses can dismantle patient myths, secure early dietitian referrals, and collaborate to optimize supportive care like vitamin D.

A JAMA Surgery study of 2.7M patients reveals decade-long increases in surgical delays, with significant racial and socioeconomic disparities.

Oncology clinical trial nurse navigator Elise Curry, RN, breaks down the key clinical questions surrounding the FDA approval of oral iberdomide.

Oncology clinical trial nurse navigator Elise Curry, RN, explains the impact of the FDA's approval of oral iberdomide for multiple myeloma.

A meta-analysis shows traditional pathology counts fail to predict which patients benefit from adding hormone therapy to postoperative radiation.

The FDA granted accelerated approval to iberdomide with daratumumab and dexamethasone for relapsed/refractory multiple myeloma.

Oncology social worker Kelly Dyckman, LCSW, shares key strategies for identifying patient distress, demystifying counseling, and managing trauma.